ASP Isotopes (ASPI) Current Deferred Revenue (2023 - 2026)

ASP Isotopes' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 567.66% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 567.66% increase from a year earlier, with the FY2025 full-year figure at $882000.0, down 78.72% from the prior year.
• Current Deferred Revenue climbed to $7.4 million in Q1 2026 per ASPI's latest filing, from $882000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $7.4 million in Q1 2026 and bottomed at $882000.0 in Q4 2023.
• The 4-year median for Current Deferred Revenue is $882000.0 (2023), against an average of $2.0 million.
• Across the five-year window, Current Deferred Revenue plunged 78.72% in 2025 and soared 567.66% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $882000.0 in 2023, then surged by 369.84% to $4.1 million in 2024, then plunged by 78.72% to $882000.0 in 2025, then surged by 733.9% to $7.4 million in 2026.
• Per Business Quant, the three latest ASPI Current Deferred Revenue figures stand at $7.4 million (Q1 2026), $882000.0 (Q4 2025), and $882000.0 (Q3 2025).